Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count: Results of a Subset Analysis of a Randomized Trial

Auayporn P. Nademanee, John F. DiPersio, Richard Maziarz, Edward A. Stadtmauer, Ivana N. Micallef, Patrick J. Stiff, Frank J. Hsu, Gary Bridger, Brian J. Bolwell

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Preapheresis peripheral blood (PB) CD34+ cell count is a strong predictor of hematopoietic stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success of HSC collection in patients with multiple myeloma. However, a uniform PB CD34+ cell count that predicts mobilization failure has not been defined, resulting in the development of institute-specific algorithms for mobilization, particularly regarding the decision of when to use the novel stem cell mobilization agent plerixafor. In this post hoc analysis, we evaluated the mobilization efficacy of plerixafor plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in patients with multiple myeloma, stratified by preapheresis PB CD34+ cell count: + cell count, the total yield of CD34+ cells from apheresis was significantly higher in the plerixafor group than in the placebo group, and significantly more patients in the plerixafor group collected the minimum (≥2 × 106 cells/kg) and optimum (≥6 × 106 cells/kg) stem cell yields on each day of apheresis. As a corollary, the greater stem cell collection in plerixafor-treated patients resulted in the need for significantly fewer days of apheresis to reach minimum and optimum cell doses across all cell count groups. For all CD34+ cell count groups, the proportion of patients proceeding to transplantation and the median time to platelet and neutrophil engraftment were similar in the plerixafor and placebo groups. Our findings demonstrate that in patients with multiple myeloma who might be predicted to fail mobilization based on low PB CD34+ cell count, the addition of plerixafor to G-CSF allows for collection of the minimal and optimal cell doses in a greater proportion of patients compared with G-CSF alone. In addition, plerixafor plus G-CSF significantly improves the likelihood of optimal HSC collection in patients with higher preapheresis PB CD34+ cell counts (≥20 cells/μL) compared with placebo plus G-CSF. Collectively, this analysis of predicted poor mobilizers validates the superiority of plerixafor plus G-CSF compared with G-CSF alone, which had been demonstrated previously in the overall patient population.

Original languageEnglish (US)
Pages (from-to)1564-1572
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Hematopoietic Stem Cell Mobilization
Blood Cell Count
Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Placebos
Blood Component Removal
Cell Count
Hematopoietic Stem Cells
Stem Cells
JM 3100
Neutrophils
Blood Platelets
Transplantation
Costs and Cost Analysis

Keywords

  • AMD 3100
  • Poor mobilzer
  • Stem cell mobilization

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count : Results of a Subset Analysis of a Randomized Trial. / Nademanee, Auayporn P.; DiPersio, John F.; Maziarz, Richard; Stadtmauer, Edward A.; Micallef, Ivana N.; Stiff, Patrick J.; Hsu, Frank J.; Bridger, Gary; Bolwell, Brian J.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 10, 10.2012, p. 1564-1572.

Research output: Contribution to journalArticle

@article{d92710e4d3324317a539c5d33709cc0b,
title = "Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count: Results of a Subset Analysis of a Randomized Trial",
abstract = "Preapheresis peripheral blood (PB) CD34+ cell count is a strong predictor of hematopoietic stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success of HSC collection in patients with multiple myeloma. However, a uniform PB CD34+ cell count that predicts mobilization failure has not been defined, resulting in the development of institute-specific algorithms for mobilization, particularly regarding the decision of when to use the novel stem cell mobilization agent plerixafor. In this post hoc analysis, we evaluated the mobilization efficacy of plerixafor plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in patients with multiple myeloma, stratified by preapheresis PB CD34+ cell count: + cell count, the total yield of CD34+ cells from apheresis was significantly higher in the plerixafor group than in the placebo group, and significantly more patients in the plerixafor group collected the minimum (≥2 × 106 cells/kg) and optimum (≥6 × 106 cells/kg) stem cell yields on each day of apheresis. As a corollary, the greater stem cell collection in plerixafor-treated patients resulted in the need for significantly fewer days of apheresis to reach minimum and optimum cell doses across all cell count groups. For all CD34+ cell count groups, the proportion of patients proceeding to transplantation and the median time to platelet and neutrophil engraftment were similar in the plerixafor and placebo groups. Our findings demonstrate that in patients with multiple myeloma who might be predicted to fail mobilization based on low PB CD34+ cell count, the addition of plerixafor to G-CSF allows for collection of the minimal and optimal cell doses in a greater proportion of patients compared with G-CSF alone. In addition, plerixafor plus G-CSF significantly improves the likelihood of optimal HSC collection in patients with higher preapheresis PB CD34+ cell counts (≥20 cells/μL) compared with placebo plus G-CSF. Collectively, this analysis of predicted poor mobilizers validates the superiority of plerixafor plus G-CSF compared with G-CSF alone, which had been demonstrated previously in the overall patient population.",
keywords = "AMD 3100, Poor mobilzer, Stem cell mobilization",
author = "Nademanee, {Auayporn P.} and DiPersio, {John F.} and Richard Maziarz and Stadtmauer, {Edward A.} and Micallef, {Ivana N.} and Stiff, {Patrick J.} and Hsu, {Frank J.} and Gary Bridger and Bolwell, {Brian J.}",
year = "2012",
month = "10",
doi = "10.1016/j.bbmt.2012.05.017",
language = "English (US)",
volume = "18",
pages = "1564--1572",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count

T2 - Results of a Subset Analysis of a Randomized Trial

AU - Nademanee, Auayporn P.

AU - DiPersio, John F.

AU - Maziarz, Richard

AU - Stadtmauer, Edward A.

AU - Micallef, Ivana N.

AU - Stiff, Patrick J.

AU - Hsu, Frank J.

AU - Bridger, Gary

AU - Bolwell, Brian J.

PY - 2012/10

Y1 - 2012/10

N2 - Preapheresis peripheral blood (PB) CD34+ cell count is a strong predictor of hematopoietic stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success of HSC collection in patients with multiple myeloma. However, a uniform PB CD34+ cell count that predicts mobilization failure has not been defined, resulting in the development of institute-specific algorithms for mobilization, particularly regarding the decision of when to use the novel stem cell mobilization agent plerixafor. In this post hoc analysis, we evaluated the mobilization efficacy of plerixafor plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in patients with multiple myeloma, stratified by preapheresis PB CD34+ cell count: + cell count, the total yield of CD34+ cells from apheresis was significantly higher in the plerixafor group than in the placebo group, and significantly more patients in the plerixafor group collected the minimum (≥2 × 106 cells/kg) and optimum (≥6 × 106 cells/kg) stem cell yields on each day of apheresis. As a corollary, the greater stem cell collection in plerixafor-treated patients resulted in the need for significantly fewer days of apheresis to reach minimum and optimum cell doses across all cell count groups. For all CD34+ cell count groups, the proportion of patients proceeding to transplantation and the median time to platelet and neutrophil engraftment were similar in the plerixafor and placebo groups. Our findings demonstrate that in patients with multiple myeloma who might be predicted to fail mobilization based on low PB CD34+ cell count, the addition of plerixafor to G-CSF allows for collection of the minimal and optimal cell doses in a greater proportion of patients compared with G-CSF alone. In addition, plerixafor plus G-CSF significantly improves the likelihood of optimal HSC collection in patients with higher preapheresis PB CD34+ cell counts (≥20 cells/μL) compared with placebo plus G-CSF. Collectively, this analysis of predicted poor mobilizers validates the superiority of plerixafor plus G-CSF compared with G-CSF alone, which had been demonstrated previously in the overall patient population.

AB - Preapheresis peripheral blood (PB) CD34+ cell count is a strong predictor of hematopoietic stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success of HSC collection in patients with multiple myeloma. However, a uniform PB CD34+ cell count that predicts mobilization failure has not been defined, resulting in the development of institute-specific algorithms for mobilization, particularly regarding the decision of when to use the novel stem cell mobilization agent plerixafor. In this post hoc analysis, we evaluated the mobilization efficacy of plerixafor plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in patients with multiple myeloma, stratified by preapheresis PB CD34+ cell count: + cell count, the total yield of CD34+ cells from apheresis was significantly higher in the plerixafor group than in the placebo group, and significantly more patients in the plerixafor group collected the minimum (≥2 × 106 cells/kg) and optimum (≥6 × 106 cells/kg) stem cell yields on each day of apheresis. As a corollary, the greater stem cell collection in plerixafor-treated patients resulted in the need for significantly fewer days of apheresis to reach minimum and optimum cell doses across all cell count groups. For all CD34+ cell count groups, the proportion of patients proceeding to transplantation and the median time to platelet and neutrophil engraftment were similar in the plerixafor and placebo groups. Our findings demonstrate that in patients with multiple myeloma who might be predicted to fail mobilization based on low PB CD34+ cell count, the addition of plerixafor to G-CSF allows for collection of the minimal and optimal cell doses in a greater proportion of patients compared with G-CSF alone. In addition, plerixafor plus G-CSF significantly improves the likelihood of optimal HSC collection in patients with higher preapheresis PB CD34+ cell counts (≥20 cells/μL) compared with placebo plus G-CSF. Collectively, this analysis of predicted poor mobilizers validates the superiority of plerixafor plus G-CSF compared with G-CSF alone, which had been demonstrated previously in the overall patient population.

KW - AMD 3100

KW - Poor mobilzer

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=84866169152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866169152&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.05.017

DO - 10.1016/j.bbmt.2012.05.017

M3 - Article

C2 - 22683613

AN - SCOPUS:84866169152

VL - 18

SP - 1564

EP - 1572

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -